

AUTHOR INDEX

Articles appearing on AJKD Electronic Pages are referred to by journal number, a colon, the letter E, and a number.

Page references to Supplement 1 (January 2006), Supplement 2 (April 2006), and Supplement 3 (May 2006) are preceded, respectively, by S1:, S2:, and S3:.

- Aasarød, K., 396
Abbott, K.C., 593
Aboud, H., 263
Acharya, M., 263, 565
Acikel, C., 42
Ackoundou-N'Guessan, C., 879
Adams, P.L., S2:65
Adu, D., 385
Agarwal, A.K., 419
Agarwal, G., 419
Agarwal, R., 565
Aitchison, J., 983
Akman, B., 5:E65
Alfaro, G., 78
Allon, M., 469, 1020
Almeida, A.G., 587
Alpers, C.E., 983
Altmann, P., 385
Alvestrand, A., 60
Ambrus, C., 655
Amore, A., 993
Amoroso, A., 761
Anderstam, B., 60
Andress, D.L., 263
Andrulli, S., 993
Angelet, P., 241
Ansell, D., 445
Antignac, C., 1004
Arab, L., 24
Araya, C.E., 553
Armitage, J., 385
Arruda, J.A.L., 539
Aruny, J.E., 3:xiv, 3:E35
Asai, A., 122
Aslam, N., 4:xlix, 4:E43
Assaly, R., 6:E83
Astor, B., 285
Atabak, S., 428
Atkins, R.C., 604
Atkinson, M.A., 870
Attallah, N., 644
Aucella, F., 1045
Auvinen, A., 972
Avron, J., 301
Aydin, A., 42
Azap, O.K., 5:E65

Baigent, C., 385
Bailey, J., 131
Baker, C.S., 830
Bakkaloglu, A., 1004
Balestrieri, G., 770

Baliga, P.K., 324
Ball, S., 385
Barany, P., 139
Bardají, A., 241
Barker, J., 1020
Barragán, G., 78
Basi, S., 927
Bastacky, S.I., 4:xlix, 4:E43
Batlle, D., 263
Baxter, A., 385
Beck, G.J., 131
Beddu, S., 131, 614
Behar, D.M., 88
Bellizzi, V., 1045
Benz, R.L., 614
Berl, T., 565
Besarab, A., 644
Bilgic, A., 5:E65
Bingham, C., 5:E67
Birck, R., 15
Bissler, J.J., 95
Blackwell, L., 385
Blankestijn, P.J., 1013
Blaszak, C.K., 503
Blaszak, R.T., 503
Blumenthal, S., 565
Boal, T.R., 593
Boeschoten, E.W., 823
Bofinger, A., 809
Bohen, E.M., 593
Boletis, J., 167
Boletis, J.N., 309
Bolton, W.K., 171
Bonomini, M., 842
Bonzel, K.-E., 625
Borawski, J., 37
Bottero, P., 770
Brecker, S.J.D., 493
Bremner, W.J., 251
Brewster, U.C., 3:xlv, 3:E35
Broch, M., 241
Brockenbrough, A.T., 251
Broumand, B., 428
Browning, M.M., 455
Brümmer, U., 842
Brunzell, J.D., 223
Buzio, C., 770

Cagliari, K., 42
Cagnoli, L., 993
Cairns, H.S., 385
Cairns, T., 184

Cakir, E., 42
Camici, P.G., 830
Campbell, S.B., 809
Cappelli, P., 842
Carlsen, S., 396
Carr, S., 385
Casani, A., 1027
Caskey, F.J., 445
Chadban, S.J., 604
Chan, C.-P., 815
Chan, C.S., 2:xxxii, 2:E21
Chan, R.W.Y., 578
Chang, A., 983
Chang, L.-C., 1055
Charytan, D.M., 301
Chavin, K.D., 324
Chen, C.-F., 1055
Chen, C.-H., 478
Chen, J.-S., 1055
Chen, L.-P., 815
Chen, Y.-C., 4:E47, 1036
Cheng, Y.L., 751
Chertow, G.M., 149, 157
Cheung, A.K., 131
Chiang, C.-K., 815
Chien, C.-T., 1055
Chin, A.I., 697
Chobanian, M.C., 915
Chou, S.-Y., 798
Chow, K.-M., 578
Chow, K.M., 751
Chuang, C.-C., 666
Chuang, S.-Y., 478
Chung, K.-Y., 578
Clapp, W.L., 553
Clatworthy, M.R., 680
Cohen, C., 1075
Cohn, A., 317
Collins, A.J., 375
Collins, R., 385
Collinson, P.O., 493
Compte, T., 241
Concato, J., 356
Condini, V., 842
Conte, G., 1045
Conti, G., 993
Cook, H.T., 184
Cook, W.J., 692
Coppo, R., 993
Cortés-Sanabria, L., 78
Costantini, A., 842
Couser, W.G., 375
Coyne, D., 263

AUTHOR INDEX

Articles appearing on AJKD Electronic Pages are referred to by journal number, a colon, the letter E, and a number.

Page references to Supplement 1 (January 2006), Supplement 2 (April 2006), and Supplement 3 (May 2006) are preceded, respectively, by S1:, S2:, and S3:.

- Aasarød, K., 396
Abbott, K.C., 593
Aboud, H., 263
Acharya, M., 263, 565
Acikel, C., 42
Ackoundou-N'Guessan, C., 879
Adams, P.L., S2:65
Adu, D., 385
Agarwal, A.K., 419
Agarwal, G., 419
Agarwal, R., 565
Aitchison, J., 983
Akman, B., 5:E65
Alfaró, G., 78
Allon, M., 469, 1020
Almeida, A.G., 587
Alpers, C.E., 983
Altmann, P., 385
Alvestrand, A., 60
Ambrus, C., 655
Amore, A., 993
Amoroso, A., 761
Anderstam, B., 60
Andress, D.L., 263
Andrulli, S., 993
Angelet, P., 241
Ansell, D., 445
Antignac, C., 1004
Arab, L., 24
Araya, C.E., 553
Armitage, J., 385
Arruda, J.A.L., 539
Aruny, J.E., 3:xiv, 3:E35
Asai, A., 122
Aslam, N., 4:xlix, 4:E43
Assaly, R., 6:E83
Astor, B., 285
Atabak, S., 428
Atkins, R.C., 604
Atkinson, M.A., 870
Attallah, N., 644
Aucella, F., 1045
Auvinen, A., 972
Avron, J., 301
Aydin, A., 42
Azap, O.K., 5:E65

Baigent, C., 385
Bailey, J., 131
Baker, C.S., 830
Bakkaloglu, A., 1004
Balestrieri, G., 770

Baliga, P.K., 324
Ball, S., 385
Barany, P., 139
Bardají, A., 241
Barker, J., 1020
Barragán, G., 78
Basi, S., 927
Bastacky, S.I., 4:xlix, 4:E43
Batlle, D., 263
Baxter, A., 385
Beck, G.J., 131
Beddu, S., 131, 614
Behar, D.M., 88
Bellizzi, V., 1045
Benz, R.L., 614
Berl, T., 565
Besarab, A., 644
Bilgic, A., 5:E65
Bingham, C., 5:E67
Birck, R., 15
Bissler, J.J., 95
Blackwell, L., 385
Blankestijn, P.J., 1013
Blaszak, C.K., 503
Blaszak, R.T., 503
Blumenthal, S., 565
Boal, T.R., 593
Boeschoten, E.W., 823
Bofinger, A., 809
Bohen, E.M., 593
Boletis, J., 167
Boletis, J.N., 309
Bolton, W.K., 171
Bonomini, M., 842
Bonzel, K.-E., 625
Borawski, J., 37
Bottero, P., 770
Brecker, S.J.D., 493
Bremner, W.J., 251
Brewster, U.C., 3:xlv, 3:E35
Broch, M., 241
Brockenbrough, A.T., 251
Broumand, B., 428
Browning, M.M., 455
Brümmer, U., 842
Brunzell, J.D., 223
Buzio, C., 770

Cagliari, K., 42
Cagnoli, L., 993
Cairns, H.S., 385
Cairns, T., 184

Cakir, E., 42
Camici, P.G., 830
Campbell, S.B., 809
Cappelli, P., 842
Carlsen, S., 396
Carr, S., 385
Casani, A., 1027
Caskey, F.J., 445
Chadban, S.J., 604
Chan, C.-P., 815
Chan, C.S., 2:xxxii, 2:E21
Chan, R.W.Y., 578
Chang, A., 983
Chang, L.-C., 1055
Charytan, D.M., 301
Chavin, K.D., 324
Chen, C.-F., 1055
Chen, C.-H., 478
Chen, J.-S., 1055
Chen, L.-P., 815
Chen, Y.-C., 4:E47, 1036
Cheng, Y.L., 751
Chertow, G.M., 149, 157
Cheung, A.K., 131
Chiang, C.-K., 815
Chien, C.-T., 1055
Chin, A.I., 697
Chobanian, M.C., 915
Chou, S.-Y., 798
Chow, K.-M., 578
Chow, K.M., 751
Chuang, C.-C., 666
Chuang, S.-Y., 478
Chung, K.-Y., 578
Clapp, W.L., 553
Clatworthy, M.R., 680
Cohen, C., 1075
Cohn, A., 317
Collins, A.J., 375
Collins, R., 385
Collinson, P.O., 493
Compte, T., 241
Concato, J., 356
Condini, V., 842
Conte, G., 1045
Conti, G., 993
Cook, H.T., 184
Cook, W.J., 692
Coppo, R., 993
Cortés-Sanabria, L., 78
Costantini, A., 842
Couser, W.G., 375
Coyne, D., 263

- Craig, J.C., 686, 715
 Csiky, B., 294
 Cueto-Manzano, A.M., 78
 Cullis, B., 5:E67
 Curhan, G.C., 780
- Dalal, D., 848
 Danese, M.D., 149
 Daniels, F., 1:v
 Danovitch, G., S2:86
 Daugas, E., 1072
 Daugirdas, J., 469
 Davenport, A., 350
 David, S., 1027
 Davin, J.-C., 2:E27
 Davis, C.L., 191
 de Almeida, E.A.F., 587
 de Boer, I., 223
 Dekker, F.W., 396, 823
 Delladetsima, I., 309
 Delmez, J.A., 131
 de Mutsert, R., 396
 De Nicola, L., 1045
 de Oliveira, E.I., 587
 Depner, T.A., 469
 De Simone, W., 1045
 de Smet, A.A.E.A., 1013
 Deteix, P., 879
 Dharnidharka, V.R., 553
 Dieplinger, H., 888
 Di Iorio, B.R., 1045
 Di Liberato, L., 842
 Dincer, I., 485
 Ding, J., 157
 Dirks, J.H., 375
 Di Toma, L., 770
 Dittrich, K., 625
 Dittrich, M.O., 251
 Doan, Q.V., 149
 Donnelly, L.F., 95
 Donner, A., 3:E37
 Doyle, J.W., 862
 Drachenberg, C.B., 1081
 D'Souza, R., 5:E67
 Düker, G., 625
 Duman, N., 485
 Dunea, G., 539
 Dusilová-Sulková, S., 406
 Dwyer, J.T., 614
 Dylan, M., 149
- Echarri, R., 1:xxxii, 1:E1
 Eddy, A., 365
 Edenharter, G., 445
 Eknoyan, G., 614
 Elder, G., 715
 Eleftheriadis, T., 6:E77
 Elliot, V., 184
 Erbil, K., 42
- Ertürk, S., 485
 ESCAPE Trial Group, 1004
 Eustace, J., 848
 Eyileten, T., 42
- Fadem, S., 263
 Fadrowski, J.J., 115
 Fang, J.-T., 4:E47
 Farrar, H.C., 503
 Feest, T.G., 445
 Fervenza, F.C., 342
 Fialová, J., 406
 Filep, J.G., 212
 Finn, L., 365
 Fischereder, M., 1075
 Fishbane, S., 683
 Fitzgerald, B.M., 462
 Fivush, B., 285
 Fivush, B.A., 115, 870
 Florquin, S., 2:E27
 Födinger, M., 509
 Fogo, A.B., 5:xlii, 5:E61, 983
 Foramitti, M., 761
 Forman, J.P., 780
 Fouqueray, B., 738
 Frankenfield, D., 285
 Frankenfield, D.L., 115, 870
 Frascà, G., 761
 Frederick, P., 1:v
 Frei, D., 738
 Frei, U., 445, 509
 Friedman, A.L., 115
 Friedman, A.N., 1064
 Frinak, S., 644
 Fründ, S., 625
 Fukuhara, S., 122
 Fukuma, Y., 412
 Fung, S.K.-S., 751
 Furth, S., 285
 Fushima, T., 908
- Gadegbeku, C.A., 956
 Galey, J., 593
 Galje, J., 212
 García, C., 241
 Garg, A., 317
 Garini, G., 770
 Gaspari, F., 1
 Gassmann-Mayer, C., 738
 Gaston, R.S., S2:3
 Gaze, D.C., 493
 Genctoy, G., 42
 Gersch, M.S., 1:E15
 Ghiggeri, G.M., 761
 Giannarresi, G., 770
 Giannattasio, P., 1045
 Giannico, G., 5:xlii, 5:E61
 Gianoglio, B., 993
 Gladstone, E., 72
 Goldberg, R.J., 378
- Gono, T., 908
 Goodship, T.H.J., 2:E27
 Goral, S., 1:E3
 Gordon, P., 862
 Gore, J.M., 378
 Gorman, G., 285
 Goto, T., 672
 Gotoh, Y., 518
 Grabensee, B., 3:E37, 947
 Greene, T., 469, 956
 Gregorini, G., 770
 Gregson, H., 493
 Griffiths, R., 149
 Gröchenig, E., 888
 Gröne, H.-J., 1075
 Groothoff, J.W., 2:E27
 Guerini, S., 761
 Guidet, B., 1072
 Gutierrez, C., 241
- Habwe, V.Q., S2:98
 Hadjiconstantinou, V., 167
 Haffner, D., 625
 Haley, W.E., 528
 Hall, Y., 956
 Hallan, S., 396
 Hamasaki, Y., 6:xxxvii, 6:E73
 Hamilton, R., 1:E13
 Hariharan, S., S2:1, S2:22
 Harmoinen, A., 972
 Harries, S., 5:E67
 Harris, S., 103
 Hartman, J.A., 419
 Hasegawa, A., 518
 Hatae, K., 412
 Hatamizadeh, P., 428
 Hataya, H., 6:xxxvii, 6:E73
 Hattori, M., 518
 Hatzakis, A., 167, 309
 Haugen, E.N., 342
 Havekes, B., 823
 Hawley, C.M., 809
 Hebert, L.A., 8, 419
 Heering, P., 3:E37
 Heiland, A., 294
 Heimbürger, O., 139
 Heng, A.E., 879
 Hetzel, G.R., 947
 Higgins, J.P., 2:E23
 Hildebrand, L.G., 324
 Hirth, R.A., 666
 Hisano, S., 412
 Hiyama, L., 1:E9
 Ho, Y.W., 2:xxxii, 2:E21
 Hodková, M., 406
 Hofmann, N., 4:E55
 Hollen, T.L., 462
 Holmen, J., 396
 Honda, H., 139
 Honda, M., 6:xxxvii, 6:E73

- Hoppe, B., 625
 Hörl, W.H., 509, 738
 Horuz, F., 2:E27
 Hoshii, Y., 908
 Hosoya, T., 122
 Hostetter, T., 72
 Houghton, D., 983
 Howard, A.D., S2:111
 Hsia, C.-C., 905
 Hsu, Y.-H., 905, 1055
 Huang, C.-C., 4:E47, 856
 Huang, C.-S., 815
 Huang, M.-C., 905
 Huang, S.-F., 4:E47
 Huckenbeck, W., 3:E37
 Huddam, B., 5:E65
 Hudkins, K.L., 983
 Hung, K.-Y., 815
 Hung, S.-C., 1036
 Huo, Z., 455
 Huston, A., 4:xlix, 4:E43
 Hwang, W., 285
 Hynes, D.M., 455
- Ibrahim, H.N., 898
 Icardi, A., 1027
 Ikeda, M., 6:xxxvii, 6:E73
 Ikeda, S.-i., 908
 Ioannidis, I., 6:E77
 Isbel, N.M., 809
 Iseki, C., 790
 Iseki, K., 790
 Ishikura, K., 6:xxxvii, 6:E73
 Isnard, M., 879
 Ito, N., 908
 Ivens, K., 3:E37
 Iwasaki, H., 412
 Izzi, C., 761
- Jalomo-Martínez, B., 78
 Jayne, D.R.W., 680
 Johansen, K.L., 862
 John, U., 625
 Johnson, D.W., 809
 Johnson, N.D., 95
 Jones, C., 103
 Jones, K., 956
 Jülg, B., 1075
- Kaelisch, I.A., 15
 Kaisar, M.O., 809
 Kaku, Y., 412
 Kalapothaki, V., 167
 Kalousová, M., 406
 Kametani, F., 908
 Kamimaki, I., 6:xxxvii, 6:E73
 Kan, W.-C., 856
 Kaplan, B., S2:52
- Kapsoritakis, A.N., 6:E77
 Karalis, D., 167
 Karpas, Z., 972
 Karpinski, M., 317
 Karube, H., 672
 Kathrein, H., 888
 Katsoulidou, A., 167
 Kaufman, J.S., 455
 Kayser, G.A., 131, 157
 Kazderová, M., 406
 Kent-Braun, J.A., 862
 Khabiri, H., 419
 Kim, J., 149
 Kimmel, P.L., 614
 Kinjo, K., 790
 Kiyoshi, Y., 412
 Klaus, G., 625
 Knoll, G., 317
 Knüppel, T., 1004
 Koch, M., 2:E31
 Koczy, A., 655
 Koide, H., 439
 Komulainen, H., 972
 König, P., 888
 Konrad, M., 1004
 Kopp, M.S., 655
 Kopple, J.D., 375
 Kopyt, N., 565
 Kostakis, A., 309
 Kourellias, K., 385
 Kovacs, A.Z., 655
 Kowalewska, J., 983
 Kramar, R., 509
 Krediet, R.T., 823
 Krick, T.P., 898
 Kronenberg, F., 888
 Kuo, H.-L., 856
 Kurschat, C., 3:E37
 Kurttio, P., 972
 Kusek, J.W., 614, 956
 Kutlay, S., 485
 Kwan, B.C.-H., 578
 Kwan, T.-H., 51
- Laczy, B., 294
 Ladinsky, G.A., 1:E3
 Lager, D.J., 342
 Lai, F.M.-M., 578
 Lai, K.-B., 578
 Lai, K.N., 2:xxxi, 2:E21
 Lambie, S.H., 830
 Lamere, N., 428
 Lameris, T.W., 1013
 Lamina, C., 888
 Landry, M., 385
 Lash, J.P., 956
 Lea, J.P., 72
 Leaper, C., 385
 Lee, R., 5:E67
 Lee, T., 1020
- Lentine, K.L., 593
 Leslie, D., 983
 Lessard, D., 378
 Leung, C.B., 751
 Leung, K.-T., 51
 Leung, N., 342
 Levey, A.S., 131
 Levin, A., 277, 738
 Levin, R., 301
 Levine, B., 263
 Lewis, J.B., 927
 Lhotta, K., 888
 Li, P.K.-T., 578, 751
 Li, Y., 1064
 Li, Y.-J., 4:E47
 Liakopoulos, V., 6:E77
 Liaño, F., 1:xxxii, 1:E1
 Lim, K., 1:E13
 Lin, C.-S., 1055
 Lin, I.-F., 478
 Lin, Y.-P., 478
 Lindholm, B., 139
 Liotier, J., 879
 Locatelli, F., 993
 Lopes, J.A., 587
 Lorber, M., 88
 Lunsford, S.L., 324
- Maggiore, U., 770
 Mak, S.K., 751
 Malhotra, D., 6:E83
 Mallamaci, F., 332
 Mandolfo, S., 233
 Manganelli, R., 1045
 Manno, C., 233
 Maor, C., 88
 Marcas, L., 241
 Martínez-Ramírez, H.R., 78
 Martinez-Vea, A., 241
 Martins, D., 965
 Matas, A.J., 353, 898
 Matchar, D.B., 528
 Matsubara, M., 672
 Matsuda, M., 908
 Matsunaga, A., 199
 Matsushima, M., 122
 Matsushita, M., 908
 Mauer, M., 419
 Mauro, L.S., 6:E83
 Maury, E., 1072
 Mazzone, T., 539
 McClellan, W.M., 72, 549, 738
 McCullagh, P., 5:E67
 McHale, T., 4:xlix, 4:E43
 McIntyre, C.W., 830
 Mehta, R.L., 493
 Melcher, C., 72
 Mendelssohn, D.C., 277
 Mertens, P.R., 6:E77

- Messa, P., 233, 715
 Messana, J.M., 666
 Meyer, K.B., 614
 Miles, L.G., 324
 Miljkovic, P., 1004
 Miller, F.J., 5:xlii, 5:E61
 Miller, L.G., 1:E9
 Minutolo, R., 1045
 Mitchell, R.L., 686
 Mitsudome, A., 412
 Miura, Y., 122
 Miyagi, T., 790
 Moe, S.M., 1064
 Mojibian, H.R., 3:xlv, 3:E35
 Molnár, G.A., 294
 Molnar, M.Z., 655
 Monti, S., 770
 Mooraki, A., 428
 Morath, C., 4:E55
 Motoyama, O., 518
 Mount, D.B., 780
 Mucci, I., 655
 Mudge, D.W., 809
 Müller, H.G., 157
 Müller, K.-M., 4:E55
- Nadasdy, G., 419
 Nadasdy, T., 419
 Nagaraja, H.N., 419
 Nagata, S., 122
 Nagy, J., 294
 Nahman, N.S., Jr., 419
 Najafi, I., 428
 Nakamichi, T., 672
 Nakamura, S., 908
 Nakamura, T., 439
 Nergizoglu, G., 485
 Neu, A., 285
 Neu, A.M., 115, 870
 Neyer, U., 888
 Ng, Y.-H., 614
 Nicholls, A., 5:E67
 Nicosa, R.F., 983
 Niimi, K., 412
 Nissensohn, A., 965
 Node, K., 439
 Norris, K., 965
 Novak, M., 655
- Oberai, P.C., 848
 Ocaña, J., 1:xxxii, 1:E1
 Oetting, W.S., 898
 Offenstadt, G., 1072
 Offner, G., 625
 Ohta, T., 518
 Ohya, Y., 790
 Oikawa, S., 199
 Olie, K.H., 2:E27
- Oliver, D.K., 593
 Oliver, J.A., 241
 Onishi, M., 122
 Okawara, S., 672
 Ornt, D., 469
 Ornvold, K., 915
 Osman-Malik, Y., 644
 Ozcan, O., 42
 Ozdemir, N., 5:E65
 Ozgurtas, T., 42
 Ozisik, L., 5:E65
- Page, S.T., 251
 Palevsky, P.M., 4:xlix, 4:E43
 Palmer, S., 715
 Pan, D., 965
 Pan, Q., 666
 Parekh, R., 285
 Parekh, R.S., 848
 Parfrey, P.S., 171
 Parikh, C.R., 356
 Pasquali, S., 233
 Passerini, P., 233
 Pastor, R., 241
 Patwardhan, M.B., 528
 Pecoits-Filho, R., 139
 Pedersen, E.B., 636
 Pellerin, D., 493
 Pelequin, C.A., 6:E83
 Peralta, C., 241
 Perazella, M.A., 3:xlv, 3:E35
 Perico, N., 1
 Perkins, R.M., 593
 Perkins, S.M., 1064
 Peruzzi, L., 993
 Pesacreta, M., 4:xlix, 4:E43
 Pesci, A., 770
 Peterman, A., 455
 Petrie, J.J.B., 809
 Petrodaskalaki, M., 167
 Pham, P.-C.T., 727
 Pham, P.-M.T., 727
 Pham, P.-T.T., 727
 Pieper, A.-K., 625
 Pintavorn, P., 692
 Pizzarelli, F., 1027
 Polkinghorne, K.R., 604
 Ponticelli, C., 233
 Porubsky, S., 1075
 Potamianos, S.P., 6:E77
 Potempa, L.A., 212
 Pourfarziani, V., 428
 Pozniak, A.S., 666
 Prasad, G.V.R., 1:E13
 Prata, M.M., 587
 Prati, E., 761
 Psichogiou, M., 167, 309
 Psimenou, E., 309
 Psychos, A.K., 6:E77
- Qiu, P., 263
 Querfeld, U., 625
 Qureshi, A.R., 139
- Racadio, J.M., 95
 Ramos, A., 241
 Rashid-Farokhi, F., 428
 Ravani, P., 761
 Reda, D.J., 455
 Redman, R.S., 553
 Reiser, I.W., 798
 Reiser, T., 375
 Remport, A., 655
 Remuzzi, G., 1
 Riella, M.C., 375
 Robinson, S., 375
 Rocco, M.V., 614
 Roderick, P., 103
 Roderick, P.J., 445
 Roger, S.D., 738
 Rogers, T.B., 898
 Rogerson, M., 103, 385
 Rojas-Campos, E., 78
 Rosansky, S., 263
 Rosner, M.H., 174
 Ross, E.A., 462
 Rossert, J., 738, 1072
 Roys, E.C., 666
 Rüdiger, T., 3:E37
- Sabadini, E., 770
 Saglam, M., 42
 Saha, H., 972
 Saito, M., 672
 Saito, T., 199
 Sakano, T., 518
 Sakkas, G.K., 862
 Sala, P., 1027
 Salonen, L., 972
 Salvadó, E., 241
 Salvadori, M., 233
 Sam, R., 539
 Samimaghram, H., 428
 Samsa, G.P., 528
 Sanada, S., 672
 Sanadgol, H., 428
 Sandmann, W., 3:E37
 Sangill, M., 636
 Sano, K., 908
 Sarnak, M.J., 131
 Saurí, A., 241
 Sauter, M., 1075
 Savransky, E., S2:86
 Sawyers, E.S., 593
 Scally, J.P., 593
 Seesi, M., 842
 Schaefer, F., 1004
 Schaeffner, E.S., 509

- Scharf, R.E., 947
 Schena, F.P., 761
 Schlieper, G., 3:E37
 Schlondorff, D., 1075
 Schmitt, W.H., 15
 Schmude, K., 6:E83
 Schned, A.R., 915
 Schober-Halstenberg, H.-J., 445
 Schönfelder, E.-M., 1004
 Schulman, G., 565
 Schwab, S.J., 131, 469
 Schwaiger, J.P., 888
 Schwartz, M.M., 539
 Schwedler, S.B., 212
 Schwenger, V., 4:E55
 Scigliano, R., 1045
 Scoble, J.E., 385
 Scolari, F., 761
 Sebastianelli, M.E., 593
 Segawa, Y., 412
 Selby, N.M., 830
 Sengül, S., 485
 Seyrafian, S., 428
 Shah, S.V., 375
 Shapiro, C.M., 655
 Sharma, R., 493
 Shaw, J.E., 604
 Shidham, G., 8
 Shilling, L.M., 324
 Shimbo, T., 122
 Shindo, T., 672
 Shishido, S., 518
 Shlush, L.I., 88
 Shubert, T., 862
 Sibley, R.K., 2:E23
 Sibley, S.D., 223
 Sika, M., 956
 Simon, D., 365
 Simpson, K.S., 324
 Singh, A.K., 539
 Sinico, R.A., 770
 Sisterhen, L.L., 503
 Sitter, T., 1075
 Siu, Y.-P., 51
 Sjöberg, B., 60
 Skorecki, K., 88
 Slish, K., 666
 Smalls, G.R., 324
 Smith, K.D., 983
 Smith, T., 251
 Soares, S.M., 342
 Sokol, H., 1072
 Sonmez, A., 42
 Sorbara, D., 455
 Sosnov, J., 378
 Souweine, B., 879
 Spetie, D.N., 419
 Spiezia, S., 1045
 Spoto, B., 332
 Sprague, S.M., 263
 Stallone, C., 1045
 Stefanidis, I., 6:E77
 Steffes, M.W., 223
 Stenvinkel, P., 139
 Stivelman, J.C., 251
 Stockschaeder, M., 947
 Storsley, L., 317
 Stowe, C.D., 503
 Strain, L., 2:E27
 Streather, C.P., 493
 Strippoli, G.F.M., 715
 Stroupe, K.T., 455
 Stübinger, A., 625
 Sturm, W., 888
 Sturtevant, J.M., 809
 Su, Q., 604
 Sucker, C., 947
 Sugaya, T., 439
 Suliman, M., 60
 Sun, W.Y., 798
 Sunder-Plasmann, G., 509
 Suzuki, M., 672
 Suzuki, T., 908
 Syspa, V., 167, 309
 Szefert, L., 655
 Szentkiralyi, A., 655
 Szeto, C.-C., 578
 Szeto, C.C., 751
 Szeto, C.Y.-K., 578
 Tai, D.W., 1055
 Takahashi, K., 518
 Takishita, S., 790
 Talor, Z., 1:E15
 Tamaskó, M., 294
 Tang, A., 1:E9
 Tang, A.W.-C., 751
 Tang, S., 2:xxxi, 2:E21
 Tareen, N., 965
 Tarn, D.-C., 1036
 Tasar, M., 42
 Tasic, V., 1004
 Taylor, A.J., 593
 Taylor, E.N., 780
 Tedeschi, P., 666
 Tesaf, V., 406
 Testa, A., 332
 Thomas, W., 223
 Tian, Y.-C., 4:E47
 Ting, C.-C., 905
 Toffelmir, E.B., 277
 Tomson, C.R.V., 385
 Tong, A., 715
 Tong, M.K.-H., 51
 Torres, D., 761
 Tosoni, C., 770
 Toto, R.D., 614
 Traoré, O., 879
 Trapp, R., 2:E31
 Triepi, G., 332
 Troxell, M.L., 2:E23
 Tsongalis, G.J., 915
 Tsuru, N., 412
 Tu, H.-Y., 905
 Tumiati, B., 770
 Turenne, M.N., 666
 Ueda, Y., 439
 Uehara, T., 908
 Unruh, M.L., 614, 956
 Vamvaka, E., 6:E77
 Van Biesen, W., 428
 Vandenbroucke, J.P., 823
 van den Dorpel, M.A., 1013
 van den Meiracker, A.H., 1013
 van der Linden, J., 1013
 van der Woude, F.J., 15
 Vanholder, R., 428
 van Manen, J.G., 823
 Vargas, R., 965
 Vecchio, F., 770
 Venditti, G., 1045
 Verlaak, R., 2:E27
 Vigneau, C., 1072
 Vincent, L., 1:E13
 Viola, B.F., 233, 761
 Volkova, N., 24
 Vural, A., 42
 Wada, N., 518
 Wagner, L., 294
 Wagner, Z., 294
 Waldherr, R., 4:E55
 Wang, C., 848
 Wang, H.-J., 856
 Wang, K., 139
 Wang, X., 956
 Wann, J.G., 1055
 Wanner, C., 212
 Warady, B.A., 115
 Warwick, G., 385
 Watkins, B.A., 1064
 Weber, S., 1004
 Webster, A.C., 686
 Weening, J.J., 2:E27
 Weisbord, S.D., 4:xlii, 4:E43
 Wheeler, D.C., 385
 Wheeler, J.R.C., 666
 Whiting, S., 350
 Wiggins, K.J., 809
 Williams, J.M., 95
 Williams, L., 263
 Wilson, A., 375
 Winkelmayer, W.C., 301, 509
 Winograd, R., 6:E77
 Wittmann, I., 294
 Wolfe, R.A., 666

- | | | |
|-----------------------|--------------------|---------------------------|
| Wong, T.Y.-H., 751 | Yarzebski, J., 378 | Yung, J.C.-U., 751 |
| Wu, H., 539 | Yazaki, M., 908 | |
| Wühl, E., 1004 | Yeo, F.E., 593 | Zadshir, A., 965 |
| Yan, G., 131, 614 | Yeun, J.Y., 697 | Zamboli, P., 1045 |
| Yanagihara, T., 518 | Yeung, L.-K., 1055 | Zavitsanou, A., 167 |
| Yang, C.-C., 1055 | Yilmaz, M.I., 42 | Zeier, M., 4:E55 |
| Yang, C.-W., 4:E47 | Yu, A.W.-Y., 751 | Zhang, L., 848 |
| Yang, H., S2:1, S2:37 | Yu, W.-C., 478 | Zima, T., 406 |
| Yang, R., 317 | Yuan, C.M., 593 | Zimmet, P.Z., 604 |
| Yang, Y.-F., 856 | Yue, L., 539 | Zoccali, C., 42, 332, 559 |
| | Yung, C.Y., 751 | |

SUBJECT INDEX

Articles appearing on AJKD Electronic Pages are referred to by journal number, a colon, the letter E, and a number.

Page references to Supplement 1 (January 2006), Supplement 2 (April 2006), and Supplement 3 (May 2006) are preceded, respectively, by S1:, S2:, and S3:.

- AASK. *See* African American Study of Kidney Disease and Hypertension
- AASV. *See* ANCA-associated vasculitis
- Acquired hemophilia, due to ANCA-associated vasculitis, rituximab for, 680–682
- ACTH. *See* Adrenocorticotrophic hormone
- Acute myocardial infarction (AMI) in kidney disease, symptom profile of, 378–384 short-term survival and use of cardiovascular agents in elderly dialysis patients after, 301–308 use of aspirin and β -blockers after, 593–603
- Acute-onset hearing loss, with renal failure in Wegener granulomatosis, 553–558
- Acute poststreptococcal glomerulonephritis (ASPGN), with HUS, pathogenesis of, 365–370
- Acute renal failure (ARF) Cochrane Renal Group Report, 686–691 complications and outcomes of Bam earthquake victims with and without, 428–438 induced by diuretics in CHF patients, 798–808 infection related to CVCs vs. DCs in, 879–887 in liver transplantation after sirolimus therapy, 692–696
- Acute respiratory failure, in uremia, caused by fulminant pulmonary calciphylaxis and metastatic calcification, 4:E47
- Acute tubulointerstitial nephritis and uveitis syndrome, lymphoid interstitial lung disease in, 4:E55
- ADMA. *See* Asymmetric dimethylarginine
- Adolescents, outcomes of HD among, 285–293 Hispanics, 870–878
- ADPKD. *See* Autosomal dominant polycystic kidney disease
- Adrenocorticotrophic hormone (ACTH), synthetic, vs. methylprednisolone plus cytotoxic agent, in idiopathic membranous nephropathy and nephrotic syndrome, 233–240
- Advanced glycation end products, soluble receptor for, relation to HD and PD in ESRD, 406–411
- AER. *See* Albumin excretion rate
- African Americans Ethiopians, absence of HIVAN in, 88–94 race as CKD risk factor reported by primary care physicians, 72–77 racial differences in coping in kidney transplantation and willingness to ask for live organ donation, 324–331
- African American Study of Kidney Disease and Hypertension (AASK), effects of blood pressure management on HRQOL, 956–964
- AH amyloidosis. *See* Amyloidosis associated with immunoglobulin heavy chain
- Albumin, serum, as predictor of malnutrition, CVD, and mortality in ESRD, 139–148
- Albumin excretion rate (AER), in relation to gender and central obesity in DCCT/EDIC cohort, 223–232
- Albuminuria assessment of prevalence using immunonephelometry vs. HPLC, AusDiab Study, 604–613 influence of poverty on ethnic differences in prevalence of, 965–971
- Allograft, renal Hodgkin disease-like PTLD of donor origin in recipient, 3:E37 survival relation to TC, fasting plasma TG, high-density lipoprotein cholesterol and low-density lipoprotein cholesterol, 509–517 urinary β_2 -microglobulin in relation to acute rejection of, 898–904
- Allopurinol, to lower serum uric acid levels in hyperuremic CKD patients, 51–59
- Ambulatory blood pressure monitoring, long-term behavior and predictors of LVH in HD patients, 485–492
- AMI. *See* Acute myocardial infarction

- Aminothiol, levels in HD and PD patients with CKD, 60–71
- Amlodipine, for blood pressure control, effects on HRQOL in AASK, 956–964
- Amyloidosis, pathophysiology, diagnosis and therapy of bleeding in, 947–955
- Amyloidosis associated with immunoglobulin heavy chain (AH amyloidosis), with lymphoplasmacytic lymphoma secreting a monoclonal γ heavy chain carrying a truncated D segment, 908–914
- ANCA. *See* Antineutrophil cytoplasmic antibody
- ANCA-associated vasculitis (AAV), relapsing, diagnostic value of serial ANCA testing, 15–23
- Androgens, as adjuvant to ESA for anemia in HD-dependent CKD, KDOQI clinical practice guidelines and recommendations
- adult patients, S3:71–78
 - pediatric patients, S3:105
- Anemia
- in CKD, KDOQI clinical practice guidelines and recommendations
 - adjuvants to ESA, S3:71–78, S3:105
 - in adults, S3:16–85
 - in children, S3:86–108
 - ESA for, S3:54–57, S3:93–98
 - executive summary, S3:11–15
 - foreword, S3:9–10
 - Hb treatment range for ESA and iron therapy, S3:33–53, S3:90–92
 - hyporesponsiveness to ESA and iron, S3:81–85, S3:107–108
 - identifying patients and initiating evaluation, S3:17–27, S3:87–88
 - initial evaluation, S3:28–32, S3:89
 - iron agents for, S3:58–70, S3:99–104
 - kidney transplant recipients, S3:109–116
 - methods of evidence review and synthesis, S3:117–125
 - red blood cell transfusions for, S3:79–80, S3:106
 - work group biographies, S3:126–130
- EPO-hyporesponsive, in HD patients with hyperferritinemia, effect of intravenous ascorbic acid on, 644–654
- epoetin alfa for early correction of, effect on CKD progression, 738–750
- in ESRD, adherence to guidelines for management of, 455–461
- in HD
- for CKD, effects of transdermal testosterone on, 251–262
 - effects of converting EPO administration from subcutaneous to intravenous on, 1027–1035
 - relation of EPO index to, 157–166
 - in kidney disease, EPO adjuvants for, 683–685
- Angiomyolipoma, renal, in tuberous sclerosis complex, embolization of, 95–102
- Antineutrophil cytoplasmic antibody (ANCA)
- glomerulonephritis associated with, fatal relapse due to EBV and VZV infections, 915–922
 - necrotizing crescentic glomerulonephritis associated with, in CSS, 770–779
 - serial testing for diagnosis of relapsing AAV, 15–23
 - vasculitis associated with, rituximab for acquired hemophilia due to, 680–682
- Antiphospholipid syndrome (APS), paraneoplastic, in relation to kidney cortex necrosis, 1072–1074
- apoE*. *See* Apolipoprotein E
- Apolipoprotein E (*apoE*) mutation, in relation to lipoprotein glomerulopathy, 199–211, 539–548
- APS. *See* Antiphospholipid syndrome
- ARF. *See* Acute renal failure
- Arginine vasopressin-receptor antagonists, for hyponatremia due to arginine vasopressin excess, 727–737
- Arteriovenous access, change to catheter, effect on mortality of HD patients, 469–477
- Arteriovenous fistula (AVF)
- infiltration of, in HD, risk factors and consequences of, 1020–1026
 - successful, prediction by forearm venous, 1013–1019
- Arts-in-Medicine Program, in an outpatient HD unit, effect on QOL, 462–468
- Ascorbate, recycling in HD, role of enhanced GLUT 1 expression in erythrocyte membranes on, 1055–1063
- Ascorbic acid
- as adjuvant to ESA for anemia in HD-dependent CKD, KDOQI clinical practice guidelines and recommendations
 - adult patients, S3:71–78
 - pediatric patients, S3:105
 - as EPO adjuvant for anemia in kidney disease, 683–685
 - intravenous, effect on EPO-hyporesponsive anemia in HD patients with hyperferritinemia, 644–654
- ASPGN. *See* Acute poststreptococcal glomerulonephritis
- Aspirin, and β -blockers, use after AMI, 593–603
- AST-120. *See* Kremezin
- Asymmetric dimethylarginine (ADMA), and oxidative stress and endothelial dysfunction in CKD, 42–50
- Atherosclerosis
- carotid, as predictor of CVD and all-cause mortality in HD patients considering renal transplantation, 888–897
 - role of CRP in, 212–222
- Atherosclerotic cardiovascular disease, incidence among HIV patients receiving dialysis, 848–855
- Attitudes, of Canadian nephrologists toward multidisciplinary team-based CKD clinic care, 277–284
- AusDiab Study. *See* Australian Diabetes, Obesity, and Lifestyle Study
- Australian Diabetes, Obesity, and Lifestyle Study (AusDiab Study), HPLC vs. immunonephelometry in assessment of albuminuria prevalence, 604–613
- Autologous blood stem cell transplantation, with high-dose melphalan for POEMS syndrome, 672–679
- Autosomal dominant polycystic kidney disease (ADPKD)
- levofloxacin for renal cyst infected with *Streptococcus agalactiae* in, 1:E9
 - tissue Doppler imaging of left ventricular diastolic function in, 587–592
- AVF. *See* Arteriovenous fistula
- β -Blockers, and aspirin, use after AMI, 593–603
- Biocompatibility, of HD, effects of heparin, 37–41
- Biofeedback dialysis, vs. HD, occurrence of regional left ventricular dysfunction in, 830–841

- Bleeding, in amyloidosis, pathophysiology, diagnosis and therapy, 947–955
- Blood glucose, in HD patients, effect of dialysis fluid with glucose on, 636–643
- Blood pressure
ambulatory monitoring, long-term behavior and predictors of LVH in HD patients, 485–492
- in HD patients, effect of dialysis fluid with glucose on, 636–643
- management of, effects on HRQOL in AASK, 956–964
- normal, effect of ramipril on left ventricle mass in HD patients with, 478–484
- β_2 -microglobulin, urinary, in relation to acute renal allograft rejection, 898–904
- BNP. *See* B-type natriuretic peptide
- Book reviews
Kidney Diseases in the Developing World and Ethnic Minorities, 559–560
- Living Donor Kidney Transplantation: Current Practices, Emerging Trends and Evolving Challenges*, 191–192
- Non-Neoplastic Kidney Diseases*, 1081–1082
- Breast cancer, metastatic, proteinuria due to pamidronate-induced FSGS in patient with, 1075–1080
- Brucellosis, with peritonitis, in a CAPD patient, 5:E65
- CAD. *See* Coronary artery disease
- Calcification, metastatic, and fulminant pulmonary calciphylaxis causing acute respiratory failure in uremia, 4:E47
- Calcimimetic therapy, for secondary hyperparathyroidism, meta-analysis of outcomes, 715–726
- Calcinosis, in tubular and glomerular basement membranes, 2:E23
- Calciphylaxis, fulminant pulmonary, and metastatic calcification causing acute respiratory failure in uremia, 4:E47
- Calcium
serum, in relation to risks for hip, vertebral, and pelvic fractures in dialysis patients, 149–156
- v24-hour urinary excretion, in relation to prevalent hypertension, 780–789
- Calcium acetate, vs. sevelamer, in pediatric CKD patients, efficacy and safety of, 625–635
- Calciuria, and paricalcitol for secondary hyperparathyroidism in CKD, 263–276
- CAPD. *See* Continuous ambulatory peritoneal dialysis
- Carboxymethyllysine, serum, as predictor of mortality in HD patients, 294–300
- Cardiopulmonary resuscitation (CPR), families' and physicians' predictions of dialysis patients' preferences on, 122–130
- Cardiovascular agents, use in elderly dialysis patients after acute MI, 301–308
- Cardiovascular disease (CVD)
atherosclerotic, incidence among HIV patients receiving dialysis, 848–855
- in ESRD
serum albumin, CRP, IL-6 and fetuin A as predictors of, 139–148
- USRDS 2005 Annual Data Report, S1:173–184
- in HD patients considering renal transplantation, carotid atherosclerosis as predictor of, 888–897
- HD timing and, HEMO Study, 614–624
- microalbuminuria as target to improve outcomes of, 927–946
- role of CRP in, 212–222
- Carotid atherosclerosis, as predictor of CVD and all-cause mortality in HD patients considering renal transplantation, 888–897
- Catheters
central venous vs. dialysis, in ARF patients, infection related to, 879–887
- change to arteriovenous access, effect on mortality of HD patients, 469–477
- CCPD. *See* Continuous cycling peritoneal dialysis
- CCR. *See* Creatinine clearance
- Ceftazidime, intraperitoneal, for peritonitis in pediatric CCPD patients, 503–508
- Central venous catheters (CVCs), vs. DCs, in ARF patients, infection related to, 879–887
- Cerebrovascular disease, in maintenance HD, mortality due to, 131–138
- CHF. *See* Congestive heart failure
- Children. *See* Pediatric patients
- Chronic insomnia, in kidney transplant recipients, 655–665
- Chronic kidney disease (CKD)
allopurinol lowers serum uric acid levels in hyperuricemic patients, 51–59
- anemia in, KDOQI clinical practice guidelines and recommendations
adjuvants to ESA, S3:71–78, S3:105
adult patients, S3:16–85
ESA for, S3:54–57, S3:93–98
executive summary, S3:11–15
foreword, S3:9–10
Hb treatment range for ESA and iron therapy, S3:33–53, S3:90–92
- hyporesponsiveness to ESA and iron, S3:81–85, S3:107–108
- identifying patients and initiating evaluation, S3:17–27, S3:87–88
- initial evaluation, S3:28–32, S3:89
- iron agents for, S3:58–70, S3:99–104
- kidney transplant recipients, S3:109–116
- methods of evidence review and synthesis, S3:117–125
- pediatric patients, S3:86–108
- red blood cell transfusions for, S3:79–80, S3:106
- work group biographies, S3:126–130
- attitudes of Canadian nephrologists toward multidisciplinary team-based clinic care, 277–284
- cerebral white matter lesions and vascular risk factors in middle-aged predialysis patients, 241–250
- effect of epoietin alfa for early correction of anemia on progression of, 738–750
- effects of transdermal testosterone on anemia and hypogonadism in hemodialysis patients, 251–262
- efficacy and safety of calcium acetate vs. sevelamer for pediatric patients, 625–635
- endothelial dysfunction, oxidative stress and ADMA levels, 42–50

- FPI in implementation of evidence-based guideline for, 528–538, 549–552
- homocysteine and aminothiol levels in HD and PD, 60–71
- Medicare program, Healthy People 2010 goal, S1:33–46
- moderate to advanced, SCS vs. nephrology clinic in managing patients, 103–114
- to severe, dose-ranging study of Kremezin for, 565–577
- mRNA expression of target genes in urinary sediment as prognostic indicator, 578–586
- obesity, smoking, and physical inactivity as risk factors in men, 396–405
- paricalcitol for secondary hyperparathyroidism in, 263–276
- risk factors reported by primary care physicians, 72–77
- safety and efficacy of ezetimibe with simvastatin, UK-HARP-II Study, 385–395
- target Hb level for EPO therapy, 171–173
- USRDS 2005 Annual Data Report, S1:47–64
- costs of, S1:199–214
- patient characteristics, S1:81–94
- Churg-Strauss syndrome (CSS), ANCA-associated necrotizing crescentic glomerulonephritis in, 770–779
- Citrate, 24-hour urinary excretion, in relation to prevalent hypertension, 780–789
- CKD. *See* Chronic kidney disease
- Classification, ISN/RPS, of lupus nephritis, renal biopsy and, 184–190
- Clinical trials. *See* Randomized controlled trials; Randomized crossover trials; specific clinical trial
- Cochrane Renal Group Report, of randomized controlled trials, 686–691
- Community nephrologists, expanding role in long-term posttransplantation care, S2:111–124
- Complement factor H, atypical HUS associated to, in monozygotic twins, PE for, 2:E27
- Congestive heart failure (CHF)
- ARF induced by diuretics in, 798–808
- Connective tissue growth factor, mRNA expression in urinary sediment as prognostic indicator of CKD, 578–586
- Continuous ambulatory peritoneal dialysis (CAPD), isolated brucella peritonitis in, 5:E65
- Continuous cycling peritoneal dialysis (CCPD), intraperitoneal ceftazidime for peritonitis in pediatric patients, 503–508
- Continuous venovenous hemodiafiltration (CVVHDF), in critically ill patient, linezolid clearance via, 6:E83
- Contrast medium, urinary excretion of L-FABP in nephropathy induced by, 439–444
- Coping, in kidney transplantation, racial differences in, 324–331
- Core curriculum in nephrology
- renal function testing, 174–183
- study designs in patient-oriented research, 356–364
- Corticosteroids, for immunosuppression in kidney transplantation, S2:3–21
- withdrawal of, S2:37–51
- CPR. *See* Cardiopulmonary resuscitation
- C1q nephropathy, clinicopathologic correlation with NS, MCD and FSGS in children, 412–418
- C-reactive protein (CRP)
- role in atherosclerosis, inflammation and CVD, 212–222
- serum, as predictor of malnutrition, CVD and mortality in ESRD, 139–148
- Creatinine clearance (CCr), low, in relation to increased PWV, 790–797
- Crossover trials. *See* Randomized crossover trials
- CRP. *See* C-reactive protein
- CSS. *See* Churg-Strauss syndrome
- CVCs. *See* Central venous catheters
- CVD. *See* Cardiovascular disease
- CVVH. *See* Continuous venovenous hemofiltration
- CVVHDF. *See* Continuous venovenous hemodiafiltration
- Cyclosporine, for immunosuppression in kidney transplantation, S2:3–21
- maintenance, S2:37–51
- Cytotoxic agent, plus methylprednisolone, vs. synthetic ACTH, in idiopathic membranous nephropathy and NS, 233–240
- DCCT/EDIC. *See* Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications
- DCs. *See* Dialysis catheters
- Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC)
- relationship of gender, AER and central obesity, 223–232
- Diabetes mellitus
- as CKD risk factor reported by primary care physicians, 72–77
- effects on muscle size and strength, physical activity, and intramuscular fat in dialysis patients, 862–869
- type 2, with early and overt nephropathy, impact of early referral to nephrologist on renal function preservation in, 78–87
- Diagnosis, of relapsing AASV, serial ANCA testing, 15–23
- Dialysis. *See also* Hemodialysis; Peritoneal dialysis
- biofeedback vs. HD, occurrence of regional left ventricular dysfunction in, 830–841
- Cochrane Renal Group Report, 686–691
- effects of diabetes mellitus on muscle size and strength, physical activity, and intramuscular fat, 862–869
- efficiency and session length, effects on PDR of urea, phosphate, and potassium, 1045–1054
- elderly patients after acute MI, short-term survival and use of cardiovascular agents in, 301–308
- incidence of atherosclerotic CVD among HIV patients receiving, 848–855
- maintenance, pyogenic liver abscess in ESRD patients undergoing, 856–861
- relation of serum Ca, P and PTH levels to risks for hip, vertebral and pelvic fractures in patients, 149–156
- relationship of Hb/hematocrit and all-cause mortality in, 24–36
- withdrawal of, families' and physicians' predictions of patients' preferences on, 122–130
- Dialysis catheters (DCs), vs. CVCs, in ARF patients, infection related to, 879–887
- Dialysis fluid, with glucose, effect on blood pressure, blood glucose, and QOL in HD patients, 636–643

- Dialysis membrane, flux of, effects on cerebrovascular mortality in maintenance HD, 131–138
- Diastolic function, left ventricle, in ADPKD, tissue Doppler imaging of, 587–592
- Diuretics, in CHF patients, causing ARF, 798–808
- Docosahexaenoic acids, and fish consumption, determinants in long-term HD, 1064–1071
- Dosing regimen, effects on cerebrovascular mortality in maintenance HD, 131–138
- Drinking water, nephrotoxicity of uranium ingested from, 972–982
- Earthquakes. *See* Natural disasters
- EBV. *See* Epstein-Barr virus
- Echocardiography, long-term behavior and predictors of LVH in HD patients, 485–492
- Eicosapentaenoic acids, and fish consumption, determinants in long-term HD, 1064–1071
- Elderly
- dialysis patients after acute MI, short-term survival and use of cardiovascular agents in, 301–308
 - Kidney transplant candidates, challenges in counseling and management of, S2:86–97
- Embolization, of renal angiomyolipoma in tuberous sclerosis complex, 95–102
- Encapsulating peritoneal sclerosis (EPS), as complication of PD, 697–712
- Endothelial dysfunction, and oxidative stress and ADMA levels in CKD, 42–50
- End-stage renal disease (ESRD)
- adherence to guidelines for anemia management in, 455–461
 - challenges in counseling and management of older kidney transplant candidates, S2:86–97
 - gastric antral vascular ectasia (watermelon stomach) in, 6:E77
 - IMA as predictor of mortality in, 493–502
 - impact of nephrologist specialization on care of pediatric HD patients, 115–121
 - Medicare program, S1:17–32
 - Healthy People 2010 goal, S1:33–46
 - Mendelian randomization study of epidemiology in, 332–341
 - pyogenic liver abscess in patients undergoing maintenance dialysis, 856–861
 - relation of sRAGE to HD and PD in, 406–411
 - serum albumin, CRP, IL-6 and fetuin A as predictors of malnutrition, CVD and mortality in, 139–148
 - treated, epidemiology in Germany, England and Wales, 445–454
 - understanding the basic case-mix adjustment for composite rate, 666–671
- USRDS 2005 Annual Data Report
- clinical indicators and preventive health, S1:107–120
 - costs of, S1:199–214
 - CVD in, S1:173–184
 - incidence and prevalence, S1:65–80
 - international comparisons of, S1:215–226
 - kidney transplantation, S1:145–158
 - morbidity and mortality, S1:121–144
 - patient characteristics, S1:81–94
- pediatric ESRD, S1:159–172
- provider networks, S1:185–198
- treatment modalities, S1:95–106
- England, epidemiology of treated ESRD, 445–454
- Epidemiology
- in ESRD, Mendelian randomization study of, 332–341
 - of treated ESRD in Germany, England and Wales, 445–454
- EPO. *See* Erythropoietin
- Epoietin alfa, for early correction of anemia, effect on CKD progression, 738–750
- EPS. *See* Encapsulating peritoneal sclerosis
- Epstein-Barr virus (EBV) infection, and VZV infection, causing fatal relapse of ANCA-associated glomerulonephritis, 915–922
- Erythrocyte membranes, enhanced GLUT 1 expression in, role in erythrocyte ascorbate recycling in HD, 1055–1063
- Erythropoiesis-stimulating agent (ESA), for anemia in CKD, KDOQI clinical practice guidelines and recommendations
- adult patients, S3:54–57
 - adjuvants to, S3:71–78
 - Hb treatment range and, S3:33–53
 - hyporesponsiveness to, S3:81–85
 - pediatric patients, S3:93–98
 - adjuvants to, S3:105
 - Hb treatment range and, S3:90–92
 - hyporesponsiveness to, S3:107–108
- Erythropoietin (EPO)
- adjuvants to, for anemia in kidney disease, 683–685
 - for anemia
 - in ESRD, adherence to guidelines, 455–461
 - hyporesponsive, in HD patients with hyperferritinemia, effect of intravenous ascorbic acid on, 644–654
 - in CKD, target Hb level for, 171–173
 - conversion from subcutaneous to intravenous administration, effects on anemic HD patients, 1027–1035
 - epoietin alfa, for early correction of anemia, effect on CKD progression, 738–750
- Erythropoietin (EPO) index, in relation to anemia, inflammation and mortality in HD, 157–166
- ESA. *See* Erythropoiesis-stimulating agent
- ESRD. *See* End-stage renal disease
- Ethiopians, absence of HIVAN in, 88–94
- Ethnicity, in albuminuria prevalence, influence of poverty on, 965–971
- Ethyl mercury poisoning, during protein A immunoadsorption therapy in Guillain-Barré syndrome, 2:E31
- Evidence-based medicine, FPI in implementation of CKD guideline, 528–538
- Ezetimibe, with simvastatin, safety and efficacy for CKD patients, UK-HARP-II Study, 385–395
- Facilitated process improvement (FPI), in implementation of an evidence-based CKD guideline, 528–538, 549–552
- Familial IgA nephropathy, vs. sporadic IgA nephropathy, outcome, survival and risk factors, 761–769
- Family, in prediction of patient preferences on CPR and dialysis withdrawal, 122–130

- Family history, as CKD risk factor reported by primary care physicians, 72–77
- Fatty acid-binding protein, liver-type. *See* Liver-type fatty acid-binding protein
- Fetuin A, serum, as predictor of malnutrition, CVD and mortality in ESRD, 139–148
- Fire coral, exposure to, association with MCD, 1:E15
- Fish consumption, and omega-3 fatty acid status, determinants in long-term HD, 1064–1071
- Fludrocortisone, oral, effect on serum potassium in hyperkalemic HD patients, 809–814
- Focal segmental glomerulosclerosis (FSGS)
clinicopathologic correlation with C1q nephropathy in children, 412–418
in neurofibromatosis type I, 1:E17
pamidronate-induced, in patient with metastatic breast cancer, proteinuria due to, 1075–1080
- Forearm venous distensibility, predicts successful AVF, 1013–1019
- FPI. *See* Facilitated process improvement
- Fracture risk, in dialysis patients, relation to serum Ca, P and PTH levels, 149–156
- FSGS. *See* Focal segmental glomerulosclerosis
- Fulminant pulmonary calciphylaxis, and metastatic calcification causing acute respiratory failure in uremia, 4:E47
- Gastric antral vascular ectasia (watermelon stomach), in ESRD patients, 6:E77
- Gender, in relation to AER and central obesity in DCCT/EDIC cohort, 223–232
- Germany, epidemiology of treated ESRD, 445–454
- Glomerular basement membrane, calcinosis in, 2:E23
- Glomerulonephritis
acute poststreptococcal. *See* Acute poststreptococcal glomerulonephritis
ANCA-associated
 fatal relapse due to EBV and VZV infections, 915–922
 necrotizing crescentic, in CSS, 770–779
 proliferative, due to monoclonal IgA, 342–349
- Glomerulopathy. *See* Lipoprotein glomerulopathy
- Glomerulosclerosis, focal segmental. *See* Focal segmental glomerulosclerosis
- Glucose, added to dialysis fluid, effect on blood pressure, blood glucose, and QOL in HD patients, 636–643
- Glucose transporter 1 (GLUT 1), enhanced expression on erythrocyte membranes, role in erythrocyte ascorbate recycling in HD, 1055–1063
- GLUT 1. *See* Glucose transporter 1
- Graft survival, long-term, in kidney transplantation
 overcoming barriers to, S2:52–64
 QOL and, S2:98–110
- Greek patients, on HD, HHV-8 seroprevalence in, 167–170
- Group B streptococcus. *See* *Streptococcus agalactiae*
- Guillain-Barré syndrome, ethyl mercury poisoning during protein A immunoabsorption therapy in, 2:E31
- Hb. *See* Hemoglobin
- HCV. *See* Hepatitis C virus
- HD. *See* Hemodialysis
- Health care costs, of ESRD and CKD, USRDS 2005 Annual Data Report, S1:199–214
- Health care providers, for ESRD, USRDS 2005 Annual Data Report, S1:185–198
- Health-related quality of life (HRQOL), in AASK, effects of blood pressure management of, 956–964
- Healthy People 2010 goal, Medicare ESRD and CKD programs, S1:33–46
- Hearing loss, acute-onset, with renal failure in Wegener granulomatosis, 553–558
- Hematocrit, in relation to all-cause mortality in dialysis, 24–36
- Hematura
macroscopic, due to pseudoaneurysm from percutaneous nephrostomy tube placement in kidney transplant recipient, 1:E3
- Hemodialysis (HD). *See also* Maintenance hemodialysis
adequacy of, outcomes in adolescent patients, 285–293
adjuvants to ESA for anemia in CKD, KDOQI clinical practice guidelines and recommendations
 adult patients, S3:71–78
 pediatric patients, S3:105
biocompatibility of, effects of heparin, 37–41
with critical lower-limb ischemia, spinal cord stimulation in, 842–847
- effect of change in vascular access on patient mortality, 469–477
- effect of dialysis fluid with glucose on patients' blood pressure, blood glucose, and QOL, 636–643
- effect of intravenous ascorbic acid on EPO-hyporesponsive anemia in patients with hyperferritinemia, 644–654
- effect of oral fludrocortisone on serum potassium in hyperkalemic patients, 809–814
- effect of ramipril on left ventricle mass in normotensive patients, 478–484
- effects of converting EPO administration from subcutaneous to intravenous on anemic patients, 1027–1035
- effects of transdermal testosterone on anemia and hypogonadism in CKD patients, 251–262
- for ESRD
 impact of nephrologist specialization on care of pediatric patients, 115–121
 relation to sRAGE, 406–411
USRDS 2005 Annual Data Report, S1:95–106
- HHV-8 seroprevalence in Greek patients, 167–170
- homocysteine and aminothiol levels in CKD patients, 60–71
- long-term
 behavior and predictors of LVH in, 485–492
 determinants of fish consumption and omega-3 fatty acid status in, 1064–1071
outcomes among adolescent Hispanics, 870–878
- patients considering renal transplantation, carotid atherosclerosis as predictor of CVD and all-cause mortality in, 888–897
- pseudohypocalcemia due to Magnevist contrast in, 350–352
- relation of EPO index to inflammation and mortality in, 157–166

- relationship of periodontitis, malnutrition and inflammation in, 815–822
- risk factors and consequences of AVF infiltration, 1020–1026
- role of enhanced GLUT 1 expression in erythrocyte membranes on erythrocyte ascorbate recycling in, 1055–1063
- serum carboxymethyllysine as predictor of mortality in, 294–300
- serum troponin T as predictor of mortality in, 823–829
- Tfr-F index vs. conventional measures of iron responsiveness in, 1036–1044
- timing of, relation to survival and cardiovascular outcomes, HEMO Study, 614–624
- vs. biofeedback dialysis, occurrence of regional left ventricular dysfunction in, 830–841
- Hemodialysis (HD) unit, outpatient, effect of Arts-in-Medicine Program on QOL in, 462–468
- Hemoglobin (Hb)
- in relation to all-cause mortality in dialysis, 24–36
 - target level
 - for EPO therapy in CKD, 171–173
 - of ESA and iron therapy for anemia in CKD, KDOQI clinical practice guidelines and recommendations, S3:33–53, S3:90–92
- Hemolytic uremic syndrome (HUS)
- with APSGN, pathogenesis of, 365–370
 - atypical, complement factor H-associated, in monozygotic twins, PE for, 2:E27
- Hemophilia, acquired, due to ANCA-associated vasculitis, rituximab for, 680–682
- HEMO Study
- cerebrovascular mortality in maintenance HD, 131–138
 - HD timing, survival, and cardiovascular outcomes, 614–624
- Henoch-Schönlein purpura nephritis (HSPN), predictors of outcome in children and adults, 993–1003
- Heparin, effects on MPO metabolism, oxidative stress and HD biocompatibility, 37–41
- Hepatitis C virus (HCV) infection, natural course in renal transplant recipients before or after transplantation, 309–316
- Hepatocyte growth factor, mRNA expression in urinary sediment as prognostic indicator of CKD, 578–586
- HHV-8. *See* Human herpesvirus 8
- High-density lipoprotein cholesterol, relation to mortality and allograft survival in kidney transplant recipients, 509–517
- High-performance liquid chromatography (HPLC), vs. immunonephelometry, in assessment of albuminuria prevalence, AusDiab Study, 604–613
- Hip fracture, in dialysis patients, relation of serum Ca, P and PTH levels to risks of, 149–156
- Hispanic Americans, adolescent, outcomes of HD among, 870–878
- HIV. *See* Human immunodeficiency virus
- HIVAN. *See* Human immunodeficiency virus-associated nephropathy
- Hodgkin disease-like posttransplantation lymphoproliferative disorder, of donor origin in a renal allograft recipient, 3:E37
- Homocysteine, levels in HD and PD patients with CKD, 60–71
- Hospitalization, and HD adequacy in adolescent patients, 285–293
- HPLC. *See* High-performance liquid chromatography
- HRQOL. *See* Health-related quality of life
- HSPN. *See* Henoch-Schönlein purpura nephritis
- Human herpesvirus 8 (HHV-8) seroprevalence, in Greek HD patients, 167–170
- Human immunodeficiency virus–associated nephropathy (HIVAN), absence in Ethiopians, 88–94
- Human immunodeficiency virus (HIV) infection, incidence of atherosclerotic CVD among dialysis patients with, 848–855
- HUS. *See* Hemolytic uremic syndrome
- Hypercalcemia, and paricalcitol for secondary hyperparathyroidism in CKD, 263–276
- Hyperferritinemia, effect of intravenous ascorbic acid on EPO-hyporesponsive anemia in HD patients with, 644–654
- Hyperkalemia. *See also* Pseudohyperkalemia
 - effect of oral fludrocortisone on serum potassium in HD patients with, 809–814
- Hyperparathyroidism, secondary in CKD, paricalcitol for, 263–276
 - meta-analysis of outcomes of calcimimetic therapy for, 715–726
- Hyperphosphatemia, and paricalcitol for secondary hyperparathyroidism in CKD, 263–276
- Hypertension
 - and cerebral white matter lesions in middle-aged predialysis CKD patients, 241–250
 - as CKD risk factor reported by primary care physicians, 72–77
 - living kidney donors with, impact on transplantation rates, 317–323
 - prevalent, in relation to 24-hour urinary calcium and citrate, 780–789
- Hyperuricemia, with CKD patients, allopurinol lowers serum uric acid levels in, 51–59
- Hypocalcemia. *See* Pseudohypocalcemia
- Hypogonadism, in HD patients with CKD, effects of transdermal testosterone on, 251–262
- Hyponatremia, due to arginine vasopressin excess, arginine vasopressin-receptor antagonists for, 727–737
- Idiopathic loin pain–hematuria syndrome, pathogenesis of, 419–427
- Idiopathic membranous nephropathy, methylprednisolone plus cytotoxic agent vs. synthetic ACTH in, 233–240
- IgA. *See* Immunoglobulin A
- IgA nephropathy
 - effects of valsartan on proteinuria and renal failure in, 751–760
 - familial vs. sporadic, outcome, survival and risk factors, 761–769
- IL-6. *See* Interleukin-6
- IMA. *See* Ischemia-modified albumin

- Immunoabsorption therapy, with protein A, in Guillain-Barré syndrome, ethyl mercury poisoning during, 2:E31
- Immunoglobulin A (IgA), monoclonal, causing proliferative glomerulonephritis, 342–349
- Immunonephelometry, vs. HPLC, in assessment of albuminuria prevalence, AusDiab Study, 604–613
- Immunosuppressive therapy, in kidney transplantation, S2: 3–21
- long-term graft survival and, S2:52–64
 - long-term patient survival and, S2:65–85
 - maintenance, S2:37–51
- Infection, in ARF patients, due to CVCs vs. DCs, 879–887
- Inflammation
- and cerebral white matter lesions in middle-aged predialysis CKD patients, 241–250
 - in HD
 - relation to EPO index, 157–166
 - relation to periodontitis and malnutrition, 815–822
 - role of CRP in, 212–222
- Insomnia, chronic, in kidney transplant recipients, 655–665
- Interleukin-6 (IL-6), serum, as predictor of malnutrition, CVD and mortality in ESRD, 139–148
- Interstitial lung disease, lymphoid, in acute TINU syndrome, 4:E55
- Intramuscular fat, in dialysis patients, effects of diabetes mellitus on, 862–869
- Iran, earthquake in Bam, complications and outcomes of victims with and without ARF, 428–438
- Iron, for anemia in CKD, KDOQI clinical practice guidelines and recommendations
- adult patients, S3:58–70
 - Hb treatment range and, S3:33–53
 - hyporesponsiveness to, S3:81–85
 - pediatric patients, S3:99–104
 - Hb treatment range and, S3:90–92
 - hyporesponsiveness to, S3:107–108
- Iron responsiveness, in HD patients, TfR-F index vs. conventional measures of, 1036–1044
- Ischemia, critical lower-limb, spinal cord stimulation in HD patients with, 842–847
- Ischemia-modified albumin (IMA), as predictor of mortality in ESRD, 493–502
- KDOQI. *See* Kidney Disease Outcomes Quality Initiative
- Kidney cortex necrosis, in relation to paraneoplastic APS, 1072–1074
- Kidney disease. *See also* Autosomal dominant polycystic kidney disease
- in CSS, 770–779
 - EPO adjuvants for anemia in, 683–685
 - launching and inauguration of World Kidney Day, 375–377
 - microalbuminuria as target to improve outcomes of, 927–946
 - in relation to lipoprotein glomerulopathy, 199–211
 - symptom profile of AMI patients with, 378–384
- Kidney Disease Outcomes Quality Initiative (KDOQI) clinical practice guidelines and recommendations for anemia in CKD
- adult patients
- adjuvants to ESA, S3:71–78
 - ESA for, S3:54–57
 - Hb treatment range for ESA and iron therapy, S3:33–53
 - hyporesponsiveness to ESA and iron, S3:81–85
 - identifying patients and initiating evaluation, S3:17–27
 - initial evaluation, S3:28–32
 - iron agents for, S3:58–70
 - red blood cell transfusions for, S3:79–80
 - executive summary, S3:11–15
 - foreword, S3:9–10
 - kidney transplant recipients, S3:109–116
 - methods of evidence review and synthesis, S3:117–125
 - pediatric patients
 - adjuvants to ESA, S3:105
 - ESA for, S3:93–98
 - Hb treatment range for ESA and iron therapy, S3:90–92
 - hyporesponsiveness to ESA and iron, S3:107–108
 - identifying patients and initiating evaluation, S3:87–88
 - initial evaluation, S3:89
 - introduction, S3:86
 - iron agents for, S3:99–104
 - red blood cell transfusions for, S3:106
 - work group biographies, S3:126–130
 - Kidney donors
 - living
 - with hypertension or proteinuria, impact on transplantation rates, 317–323
 - racial differences in willingness to ask for, 324–331
 - marginal living, 353–355
 - Kidney function tests, core curriculum in nephrology, 174–183
 - Kidney hypodysplasia, role of *UPIIIA* mutations in pathogenesis of, 1004–1012
 - Kidney toxicity. *See* Nephrotoxicity
 - Kidney transplantation
 - carotid atherosclerosis as predictor of CVD and all-cause mortality in HD patients considering, 888–897
 - challenges in counseling and management of older candidates for, S2:86–97
 - Cochrane Renal Group Report, 686–691
 - for ESRD, USRDS 2005 Annual Data Report, S1:95–106, S1:145–158
 - immunosuppressive therapy in, S2:3–21
 - introduction, S2:1–2
 - long-term patient survival in, S2:65–85
 - long-term QOL and graft survival, S2:98–110
 - in mentally-retarded pediatric patients, outcomes of, 518–527
 - natural course of HCV infection in recipients before or after, 309–316
 - overcoming barriers to long-term graft survival in, S2: 52–64
 - racial differences in coping and willingness to ask for live organ donation, 324–331
 - rates of, impact of accepting living donors with hypertension or proteinuria on, 317–323
 - relation of urinary β_2 -microglobulin to acute allograft rejection, 898–904
 - sirolimus-induced remission of PTLD, 5:E67
 - using marginal living donors, 353–355
 - Kidney transplant recipients

- allograft, Hodgkin disease-like PTLD of donor origin in, 3:E37
- anemia in CKD in, KDOQI clinical practice guidelines and recommendations, S3:109–116
- chronic insomnia in, 655–665
- long-term care of, expanding role for community nephrologists, S2:111–124
- long-term QOL and graft survival, S2:98–110
- long-term survival of, S2:65–85
- macroscopic hematuria due to pseudoaneurysm from percutaneous nephrostomy tube placement in, 1:E3
- natural course of HCV infection before or after transplantation, 309–316
- outpatient monitoring of, S2:22–36
- relation of TC, fasting plasma TG, high-density lipoprotein cholesterol and low-density lipoprotein cholesterol to outcomes in, 509–517
- Kremezin (AST-120), for moderate to severe CKD, dose-ranging study of, 565–577
- L-Carnitine, as adjuvant to ESA for anemia in HD-dependent CKD, KDOQI clinical practice guidelines and recommendations
- adult patients, S3:71–78
 - pediatric patients, S3:105
- Left ventricle
- diastolic function in ADPKD, tissue Doppler imaging of, 587–592
 - mass, in normotensive HD patients, effect of ramipril on, 478–484
 - regional dysfunction of, occurrence in HD vs. biofeedback dialysis, 830–841
- Left ventricular hypertrophy (LVH), in HD patients, long-term behavior and predictors of, 485–492
- Levofloxacin, for renal cyst infected with *Streptococcus agalactiae* in ADPKD, 1:E9
- L-FABP. See Liver-type fatty acid-binding protein
- Linezolid, clearance via CCVHDF, in critically ill patient, 6:E83
- Lipids
- in relation to lipoprotein glomerulopathy, 199–211
 - Lipoprotein glomerulopathy, in relation to *apoE* mutation, 539–548
 - and lipids and renal diseases, 199–211
- Liver abscess, pyogenic, in ESRD patients undergoing maintenance dialysis, 856–861
- Liver transplantation, after sirolimus therapy, ARF in, 692–696
- Liver-type fatty acid-binding protein (L-FABP), urinary excretion, in contrast-medium induced nephropathy, 439–444
- Living kidney donors. *See* Kidney donors, living
- Loin pain–hematuria syndrome, idiopathic, pathogenesis of, 419–427
- Low-density lipoprotein cholesterol, relation to mortality and allograft survival in kidney transplant recipients, 509–517
- Lower-limb ischemia, critical, spinal cord stimulation in HD patients with, 842–847
- Lupus nephritis, renal biopsy and ISN/RPS classification of, 184–190
- LVH. *See* Left ventricular hypertrophy
- Lymphoid interstitial lung disease, in acute TINU syndrome, 4:E55
- Lymphoplasmacytic lymphoma, secreting a monoclonal γ heavy chain carrying a truncated D segment, AH amyloidosis with, 908–914
- Lymphoproliferative disorder. *See* Posttransplantation lymphoproliferative disorder
- Magnetic resonance imaging, cerebral white matter lesions and vascular risk factors in middle-aged predialysis CKD patients, 241–250
- Magnevit, causing pseudohypocalcemia in HD patient, 350–352
- Maintenance hemodialysis, cerebrovascular mortality in, 131–138
- Males, obesity, smoking, and physical inactivity as risk factors for CKD in, 396–405
- Malnutrition
- in ESRD, serum albumin, CRP, IL-6 and fetuin A as predictors of, 139–148
 - in HD, relation to inflammation and periodontitis, 815–822
- MCD. *See* Minimal change disease
- Medicare, ESRD program, S1:17–32
- and CKD, Healthy People 2010 goal, S1:33–46
- Melphalan, high-dose, with autologous blood SCT for POEMS syndrome, 672–679
- Membranous glomerulopathy, with spherules, pathogenesis of, 983–992
- Membranous nephropathy, idiopathic, methylprednisolone plus cytotoxic agent vs. synthetic ACTH in, 233–240
- Men. *See* Males
- Mendelian randomization, in study of ESRD epidemiology, 332–341
- Mental retardation, outcomes of kidney transplantation in pediatric patients with, 518–527
- Messenger RNA (mRNA), expression of target genes in urinary sediment as prognostic indicator of CKD, 578–586
- Meta-analysis
- outcomes of calcimimetic therapy for secondary hyperparathyroidism, 715–726
 - serial ANCA testing for diagnosis of relapsing AASV, 15–23
- Metastatic breast cancer, proteinuria due to pamidronate-induced FSGS in patient with, 1075–1080
- Metastatic calcification, and fulminant pulmonary calciphylaxis causing acute respiratory failure in uremia, 4:E47
- Methylprednisolone, plus cytotoxic agent, vs. synthetic ACTH, in idiopathic membranous nephropathy and NS, 233–240
- Metoprolol, for blood pressure control, effects on HRQOL in AASK, 956–964
- Microalbuminuria
- in relation to gender and central obesity in DCCT/EDIC cohort, 223–232
 - as target to improve cardiovascular and renal outcomes, 927–946

- Millepora* species, exposure to, association with MCD, 1:E15
- Minimal change disease (MCD)
association with fire coral exposure, 1:E15
clinicopathologic correlation with C1q nephropathy in children, 412–418
- Monoclonal γ heavy chain, carrying a truncated D segment, secreted by lymphoplasmacytic lymphoma with AH amyloidosis, 908–914
- Monoclonal immunoglobulin A (IgA), causing proliferative glomerulonephritis, 342–349
- Monozygotic twins, PE for complement factor H-associated atypical HUS in, 2:E27
- Morbidity, in ESRD, USRDS 2005 Annual Data Report, S1: 121–144
- Mortality
all-cause
in HD patients considering renal transplantation, carotid atherosclerosis as predictor of, 888–897
in relation to hematocrit/Hb levels in dialysis, 24–36
due to cerebrovascular disease in maintenance HD, 131–138
- in ESRD
prediction by IMA, 493–502
serum albumin, CRP, IL-6 and fetuin A as predictors of, 139–148
USRDS 2005 Annual Data Report, S1:121–144
in HD
effect of change in vascular access on, 469–477
and PD, serum troponin T as predictor of, 823–829
relation to EPO index, 157–166
serum carboxymethyllysine as predictor of, 294–300
and HD adequacy in adolescent patients, 285–293
in kidney transplant recipients, relation to TC, fasting plasma TG, high-density lipoprotein cholesterol and low-density lipoprotein cholesterol, 509–517
and use of cardiovascular agents in elderly dialysis patients after acute MI, 301–308
- MPO. *See* Myeloperoxidase
- mRNA. *See* Messenger RNA
- Muscle size and strength, in dialysis patients, effects of diabetes mellitus on, 862–869
- Mutations
apoE, in relation to lipoprotein glomerulopathy, 199–211, 539–548
UPIIIA, role in pathogenesis of kidney hypodysplasia, 1004–1012
- Mycophenolate mofetil, for immunosuppression in kidney transplantation, S2:3–21
maintenance, S2:37–51
- Myeloperoxidase (MPO), metabolism of, effects of heparin, 37–41
- Myocardial infarction, acute. *See* Acute myocardial infarction
- Natural disasters, earthquake in Bam, Iran, complications and outcomes of victims with and without ARF, 428–438
- Necrotizing crescentic glomerulonephritis, ANCA-associated, in CSS, 770–779
- Needle infiltration, of AVF in HD, risk factors and consequences of, 1020–1026
- Nephrocalcinosis, in tubular and glomerular basement membranes, 2:E23
- Nephrologist
Canadian, attitudes toward multidisciplinary team-based CKD clinic care, 277–284
community, expanding role in long-term posttransplantation care, S2:111–124
early referral to, impact on renal function preservation in type 2 diabetes mellitus patients with early and overt nephropathy, 78–87
specialization of, impact on care of pediatric ESRD patients receiving HD, 115–121
- Nephrology, Cochrane Renal Group Report, 686–691
- Nephrology clinic
multidisciplinary team-based care, attitudes of Canadian nephrologists toward, 277–284
vs. SCS, in managing moderate to advanced CKD patients, 103–114
- Nephropathy
C1q. *See* C1q nephropathy
early and overt, impact of early referral to nephrologist on renal function preservation in type 2 diabetes mellitus patients with, 78–87
HIV-associated, absence in Ethiopians, 88–94
IgA. *See* IgA nephropathy
induced by contrast medium, urinary excretion of L-FABP in, 439–444
- Nephrostomy tube placement, percutaneous, in kidney transplant recipient, macroscopic hematuria due to pseudoaneurysm from, 1:E3
- Nephrotic syndrome (NS)
clinicopathologic correlation with C1q nephropathy in children, 412–418
methylprednisolone plus cytotoxic agent vs. synthetic ACTH in, 233–240
minimal change. *See* Minimal change disease
- Nephrotoxicity, of uranium ingested from drinking water, 972–982
- Neurofibromatosis type I, FSGS in, 1:E17
- NS. *See* Nephrotic syndrome
- NT-proBNP. *See* Amino-terminal pro-B-type natriuretic peptide
- Nuclear pores, spherules, pathogenesis of membranous glomerulopathy with, 983–992
- Obesity
central, in relation to gender and AER in DCCT/EDIC cohort, 223–232
as risk factor for CKD in men, 396–405
- Older adults. *See* Elderly
- Omega-3 fatty acids, and fish consumption, determinants in long-term HD, 1064–1071
- Outcome
Bam earthquake victims with and without ARF, 428–438
calcimimetic therapy for secondary hyperparathyroidism, meta-analysis, 715–726
familial vs. sporadic IgA nephropathy, 761–769
HD adequacy in adolescent patients, 285–293
HD among adolescent Hispanics, 870–878

- HSPN in children and adults, predictors of, 993–1003
kidney transplantation
in mentally-retarded pediatric patients, 518–527
relation to TC, fasting plasma TG, high-density lipoprotein cholesterol and low-density lipoprotein cholesterol, 509–517
- methylprednisolone plus cytotoxic agent vs. synthetic ACTH in idiopathic membranous nephropathy and NS, 233–240
- SCS vs. nephrology clinic in managing moderate to advanced CKD patients, 103–114
timing of HD and, HEMO Study, 614–624
- Outpatient hemodialysis unit, effect of Arts-in-Medicine Program on QOL in, 462–468
- Outpatient monitoring, of kidney transplant recipients, S2: 22–36
- Oxidative stress
effects of heparin, 37–41
and endothelial dysfunction and ADMA levels in CKD, 42–50
- Pamidronate, in patient with metastatic breast cancer, proteinuria due to FSGS induced by, 1075–1080
- Paraneoplastic antiphospholipid syndrome, in relation to kidney cortex necrosis, 1072–1074
- Parathyroid hormone (PTH), serum, in relation to risks for hip, vertebral, and pelvic fractures in dialysis patients, 149–156
- Paricalcitol, for secondary hyperparathyroidism in CKD, 263–276
- Patient-oriented research, study designs in, core curriculum in nephrology, 356–364
- Patient preferences, on CPR and dialysis withdrawal, prediction by families and physicians, 122–130
- PD. *See* Peritoneal dialysis
- PDR. *See* Postdialytic rebound
- PE. *See* Plasma exchange
- Pediatric patients
adults, predictors of HSPN outcome in, 993–1003
clinicopathologic correlation of C1q nephropathy with NS, MCD and FSGS, 412–418
efficacy and safety of calcium acetate vs. sevelamer for CKD, 625–635
with ESRD
receiving HD, impact of nephrologist specialization on care of, 115–121
USRDS 2005 Annual Data Report, S1:159–172
intraperitoneal ceftazidime for peritonitis in CCPD, 503–508
- KDOQI clinical practice guidelines and recommendations for anemia in CKD
adjuvants to ESA, S3:105
ESA for, S3:93–98
Hb treatment range for ESA and iron therapy, S3:90–92
hyporesponsiveness to ESA and iron, S3:107–108
identifying patients and initiating evaluation, S3:87–88
initial evaluation, S3:89
introduction, S3:86
iron agents for, S3:99–104
red blood cell transfusions for, S3:106
- mentally-retarded, outcome of kidney transplantation in, 518–527
- Pelvic fracture, in dialysis patients, relation of serum Ca, P and PTH levels to risks of, 149–156
- Periodontitis, in relation to inflammation and malnutrition in HD patients, 815–822
- Peritoneal dialysis (PD)
for CKD patients, homocysteine and aminothiol levels in, 60–71
continuous ambulatory. *See* Continuous ambulatory peritoneal dialysis
continuous cycling. *See* Continuous cycling peritoneal dialysis
EPS as complication of, 697–712
for ESRD
relation to sRAGE, 406–411
USRDS 2005 Annual Data Report, S1:95–106
pseudomyxoma peritonei causing culture-negative peritonitis in, 905–907
serum troponin T as predictor of mortality in, 823–829
- Peritonitis
with brucellosis, in a CAPD patient, 5:E65
culture-negative, in a PD patient, caused by pseudomyxoma peritonei, 905–907
in pediatric CCPD patients, intraperitoneal ceftazidime for, 503–508
- Pharmacokinetics, linezolid clearance via CVVHDF in critically ill patient, 6:E83
- Phosphate, effects of dialysis efficiency and session length on PDR of, 1045–1054
- Phosphorus, serum, in relation to risks for hip, vertebral, and pelvic fractures in dialysis patients, 149–156
- Physical activity
dialysis patients, effects of diabetes mellitus on, 862–869
lack of, as risk factor for CKD in men, 396–405
- Physicians
in prediction of patient preferences on CPR and dialysis withdrawal, 122–130
primary care, CKD risk factors reported by, 72–77
- Pilot projects, methylprednisolone plus cytotoxic agent vs. synthetic ACTH in idiopathic membranous nephropathy and NS, 233–240
- Plasma exchange (PE), for complement factor H-associated atypical HUS in monozygotic twins, 2:E27
- POEMS syndrome, high-dose melphalan with autologous blood SCT for, 672–679
- Postdialytic rebound (PDR), of urea, phosphate, and potassium, effects of dialysis efficiency and session length on, 1045–1054
- Posttransplantation lymphoproliferative disorder (PTLD)
Hodgkin disease-like, of donor origin in a renal allograft recipient, 3:E37
sirolimus-induced remission, 5:E67
- Potassium
effects of dialysis efficiency and session length on PDR of, 1045–1054
serum, in hyperkalemic HD patients, effect of oral fludrocortisone on, 809–814
- Poverty, influence on ethnic differences in albuminuria prevalence, 965–971
- Predialysis patients, with CKD

- middle-aged, cerebral white matter lesions and vascular risk factors in, 241–250
- Primary care physicians, CKD risk factors reported by, 72–77
- Proliferative glomerulonephritis, due to monoclonal IgA, 342–349
- Protein A immunoadsorption therapy, in Guillain-Barré syndrome, ethyl mercury poisoning during, 2:E31
- Proteinuria
- due to pamidronate-induced FSGS in patient with metastatic breast cancer, 1075–1080
 - living kidney donors with, impact on transplantation rates, 317–323
 - in relation to increased PWV, 790–797
 - and renal failure, in IgA nephropathy, valsartan effects on, 751–760
 - 24-hour vs. spot urine testing, 1–7, 8–14
- Pseudoaneurysm, from percutaneous nephrostomy tube placement in kidney transplant recipient, macroscopic hematuria due to, 1:E3
- Pseudohypocalcemia, due to Magnevist contrast in HD patient, 350–352
- Pseudomyxoma peritonei, causing culture-negative peritonitis in a PD patient, 905–907
- PTH. *See Parathyroid hormone*
- PTLD. *See Posttransplantation lymphoproliferative disorder*
- Pulmonary calciphylaxis, fulminant, and metastatic calcification causing acute respiratory failure in uremia, 4:E47
- Pulse wave velocity (PWV), increased, in relation to low CCr and proteinuria, 790–797
- PWV. *See Pulse wave velocity*
- Pyogenic liver abscess, in ESRD patients undergoing maintenance dialysis, 856–861
- QOL. *See Quality of life*
- Quality of care, FPI for CKD, 549–552
- Quality of life (QOL)
- effect of Arts-in-Medicine Program in an outpatient HD unit on, 462–468
 - and graft survival, long-term, in kidney transplant recipients, S2:98–110
 - in HD patients, effect of dialysis fluid with glucose on, 636–643
 - health-related. *See Health-related quality of life*
- Racial differences, in coping and willingness to ask for live kidney donation, 324–331
- Ramipril
- for blood pressure control, effects on HRQOL in AASK, 956–964
 - effect on left ventricle mass in normotensive HD patients, 478–484
- Randomized controlled trials
- Cochrane Renal Group Report, 686–691
 - effect of oral fludrocortisone on serum potassium in hypokalemic HD patients, 809–814
 - effects of valsartan on proteinuria and renal failure in IgA nephropathy, 751–760
- methylprednisolone plus cytotoxic agent vs. synthetic ACTH in idiopathic membranous nephropathy and NS, 233–240
- Randomized crossover trials
- effect of dialysis fluid with glucose on patients' blood pressure, blood glucose, and QOL, 636–643
 - efficacy and safety of sevelamer vs. calcium acetate in pediatric CKD patients, 625–635
- Recombinant human erythropoietin. *See Erythropoietin*
- Red blood cell transfusions, for anemia in CKD, KDOQI clinical practice guidelines and recommendations
- adult patients, S3:79–80
 - pediatric patients, S3:106
- Referral, early, to nephrologist, impact on renal function preservation in type 2 diabetes mellitus patients with early and overt nephropathy, 78–87
- Relapsing ANCA-associated vasculitis (AASV), diagnostic value of serial ANCA testing, 15–23
- Renal angiomyolipoma, in tuberous sclerosis complex, embolization of, 95–102
- Renal biopsy, and ISN/RPS classification of lupus nephritis, 184–190
- Renal cortical necrosis. *See Kidney cortex necrosis*
- Renal cyst, infected with *Streptococcus agalactiae* in AD-PKD, levofloxacin for, 1:E9
- Renal dialysis, understanding the basic case-mix adjustment for composite rate, 666–671
- Renal disease. *See Kidney disease*
- Renal failure. *See also Chronic kidney disease*
- acute. *See Acute renal failure*
 - with acute-onset hearing loss in Wegener granulomatosis, 553–558
 - and proteinuria, in IgA nephropathy, valsartan effects on, 751–760
- Renal function tests. *See Kidney function tests*
- Renal hypodysplasia. *See Kidney hypodysplasia*
- Renal transplantation. *See Kidney transplantation*
- Research, patient-oriented, study designs in, core curriculum in nephrology, 356–364
- Risk factors, vascular, and cerebral white matter lesions in middle-aged predialysis CKD patients, 241–250
- Rituximab, for acquired hemophilia due to ANCA-associated vasculitis, 680–682
- Sclerosing encapsulating peritonitis. *See Encapsulating peritoneal sclerosis*
- Sclerosing peritonitis. *See Encapsulating peritoneal sclerosis*
- SCS. *See Shared care scheme*
- SCT. *See Stem cell transplantation*
- Scuba diving, association of MCD with fire coral exposure in, 1:E15
- Secondary hyperparathyroidism. *See Hyperparathyroidism, secondary*
- Seroprevalence. *See Human herpesvirus 8 (HHV-8) seroprevalence*
- Sevelamer vs. calcium acetate, in pediatric CKD patients, efficacy and safety of, 625–635
- Shared care scheme (SCS), vs. nephrology clinic, in managing moderate to advanced CKD patients, 103–114

- Simvastatin, with ezetimibe, safety and efficacy for CKD patients, UK-HARP-II Study, 385–395
- Sirolimus
ARF in liver transplantation after treatment with, 692–696
for immunosuppression in kidney transplantation, S2: 3–21
maintenance, S2:37–51
- PTLD remission induced by, 5:E67
- SLE. *See* Systemic lupus erythematosus
- Smoking, as risk factor for CKD in men, 396–405
- Soluble receptor for advanced glycation end products (sRAGE), relation to HD and PD in ESRD, 406–411
- Specialization, of nephrologist, impact on care of pediatric ESRD patients receiving HD, 115–121
- Spherules, pathogenesis of membranous glomerulopathy with, 983–992
- Spinal cord stimulation, in HD patients with critical lower-limb ischemia, 842–847
- Sporadic IgA nephropathy, vs. familial IgA nephropathy, outcome, survival and risk factors, 761–769
- Spot urine testing, vs. 24-hour, for proteinuria, 1–7, 8–14
- sRAGE. *See* Soluble receptor for advanced glycation end products
- Stem cell transplantation (SCT), autologous blood, with high-dose melphalan for POEMS syndrome, 672–679
- Streptococcus agalactiae*, renal cyst infection in ADPKD, levofloxacin for, 1:E9
- Study designs, in patient-oriented research, core curriculum in nephrology, 356–364
- Survey, attitudes of Canadian nephrologists toward multidisciplinary team-based CKD clinic care, 277–284
- Survival
and cardiovascular outcomes, relation to HD timing, HEMO Study, 614–624
in familial vs. sporadic IgA nephropathy, 761–769
long-term, of kidney transplant recipients, S2:65–85
short-term, in elderly dialysis patients after acute MI, 301–308
- Systematic review, relationship of hematocrit/Hb and all-cause mortality in dialysis, 24–36
- Systemic lupus erythematosus (SLE), renal biopsy and ISN/RPS classification of nephritis associated with, 184–190
- Tacrolimus, for immunosuppression in kidney transplantation, S2:3–21
maintenance, S2:37–51
- TC. *See* Total cholesterol
- Testosterone, transdermal, effects on anemia and hypogonadism in HD patients with CKD, 251–262
- TfR-F. *See* Transferrin receptor-ferritin
- TG. *See* Triglyceride
- Thiols, levels in HD and PD patients with CKD, 60–71
- TINU syndrome. *See* Tubulointerstitial nephritis and uveitis syndrome
- Tissue Doppler imaging, of left ventricular diastolic function in ADPKD, 587–592
- Total cholesterol (TC), relation to mortality and allograft survival in kidney transplant recipients, 509–517
- Transferrin receptor-ferritin (TfR-F) index, vs. conventional measures of iron responsiveness in HD patients, 1036–1044
- Transfusion, of red blood cells, for anemia in CKD, KDOQI clinical practice guidelines and recommendations adult patients, S3:79–80
pediatric patients, S3:106
- Transplantation. *See* Kidney transplantation; Liver transplantation; Stem cell transplantation
- Triglyceride (TG), fasting plasma, relation to mortality and allograft survival in kidney transplant recipients, 509–517
- Troponin T, serum, as predictor of mortality in HD and PD patients, 823–829
- Tuberous sclerosis complex, embolization of renal angiomyolipoma in, 95–102
- Tubular basement membrane calcinosis in, 2:E23
- Tubulointerstitial nephritis and uveitis syndrome (TINU syndrome), lymphoid interstitial lung disease in, 4:E55
- 24-hour urine testing, vs. spot testing, for proteinuria, 1–7, 8–14
- Twins, monozygotic, PE for complement factor H-associated atypical HUS in, 2:E27
- UK-HARP-II Study. *See* United Kingdom Heart and Renal Protection Study
- United Kingdom Heart and Renal Protection Study (UK-HARP-II Study), safety and efficacy of ezetimibe with simvastatin for CKD patients, 385–395
- United States Renal Data System (USRDS), 2005 Annual Data Report, S1:3–286
- UPIIIA. *See* Uroplakin IIIA
- Uranium, ingested from drinking water, nephrotoxicity of, 972–982
- Urea, effects of dialysis efficiency and session length on PDR of, 1045–1054
- Uremia, fulminant pulmonary calciphylaxis and metastatic calcification causing acute respiratory failure in, 4:E47
- Uric acid, serum, in hyperuricemic CKD patients, allopurinol to lower levels of, 51–59
- Urinary sediment, mRNA expression of target genes as prognostic indicator of CKD, 578–586
- Urine test, spot vs. 24-hour, for proteinuria, 1–7, 8–14
- Uroplakin IIIA (UPIIIA)* mutations, role in pathogenesis of kidney hypodysplasia, 1004–1012
- USRDS. *See* United States Renal Data System
- Valsartan, effects on proteinuria and renal failure in IgA nephropathy, 751–760
- Varicella zoster virus infection (VZV infection), and EBV infection, causing fatal relapse of ANCA-associated glomerulonephritis, 915–922
- Vascular access, change in, effect on mortality of HD patients, 469–477
- Vasculitis, ANCA-associated
relapsing, diagnostic value of serial ANCA testing, 15–23
rituximab for acquired hemophilia due to, 680–682

- Venous distensibility, in forearm, predicts successful AVF, 1013–1019
Vertebral fracture, in dialysis patients, relation of serum Ca, P and PTH levels to risks of, 149–156
Vitamin C. *See* Ascorbic acid
von Recklinghausen disease. *See* Neurofibromatosis type I
VZV. *See* Varicella zoster virus
- Wales, epidemiology of treated ESRD, 445–454
Watermelon stomach. *See* Gastric antral vascular ectasia
Wegener granulomatosis, acute-onset hearing loss with renal failure in, 553–558
White matter lesions, cerebral, and vascular risk factors in middle-aged predialysis CKD patients, 241–250
World Kidney Day, launching and inauguration, 375–377

